Literature DB >> 8074927

Neutralization of HIV-1.

H Golding1, M P D'Souza, J Bradac, B Mathieson, P Fast.   

Abstract

A Workshop on Neutralization of HIV-1: Technology and reagents for analysis of prophylactic vaccines clinical trials, sponsored by the Food and Drug Administration (FDA) and the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), was held on April 19-20, 1993, in Bethesda, Maryland. This workshop brought together researchers who are involved in the development, testing, and evaluation of HIV-1 prophylactic vaccines. The major objectives were (1) to discuss critically the different neutralization and binding assays that are currently used in the evaluation of immune sera; (2) to identify assays that will measure the "most relevant" antibodies, which are likely to predict neutralization of primary isolates; and (3) to identify well-characterized reference reagents, which could be used to standardize neutralization assays used in laboratories around the world.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8074927     DOI: 10.1089/aid.1994.10.633

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

Review 1.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

2.  Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.

Authors:  J Y Zhou; D C Montefiori
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  The quest for an antibody-based HIV vaccine.

Authors:  Barton F Haynes; John R Mascola
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

4.  Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.

Authors:  S H Pincus; R Cole; R Ireland; F McAtee; R Fujisawa; J Portis
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; L Zaccaro; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates.

Authors:  D Del Mauro; D Matteucci; S Giannecchini; F Maggi; M Pistello; M Bendinelli
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.

Authors:  G B Karlsson; F Gao; J Robinson; B Hahn; J Sodroski
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.

Authors:  M Honda; K Matsuo; T Nakasone; Y Okamoto; H Yoshizaki; K Kitamura; W Sugiura; K Watanabe; Y Fukushima; S Haga; Y Katsura; H Tasaka; K Komuro; T Yamada; T Asano; A Yamazaki; S Yamazaki
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

9.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

Review 10.  Human immunodeficiency virus vaccines.

Authors:  Paul Goepfert; Anju Bansal
Journal:  Infect Dis Clin North Am       Date:  2014-10-05       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.